Article
Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.
Antimicrobial agents and chemotherapy - 1 Jun 2008
Hombrouck Anneleen, Voet Arnout, Van Remoortel Barbara, Desadeleer Christel, De Maeyer Marc, Debyser Zeger, Witvrouw Myriam
Abstract excerpt
To gain further insight into the understanding of the antiviral resistance patterns and mechanisms of the integrase strand transfer inhibitor L-870,810, the prototypical naphthyridine analogue, we passaged the human immunodeficiency virus type 1 strain HIV-1(III(B)) in cell culture in the presence of increasing concentrations of L-870,810 (III(B)/L-870,810). The mutations L74M, E92Q, and S230N were successively...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.